Indian pharma has little reason to fear Trump
We haven't written up this one. The Economic Times has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
More in Health & Medicine
Pope Leo urges global action to confront Congo’s Ebola outbreak
Pope Leo called on Sunday for international action to help contain the impact of an Ebola outbreak in the Democratic Republic of Congo, which has so far claimed more than 2,500 lives.
Why Earlier CAR-T Conversations Matter in Multiple Myeloma: Perspectives from a Patient and Community Oncologist
A patient and community oncologist share how trust, partnership and shared decision-making shaped a CAR-T journey in multiple myeloma.
GC Biopharma Wins India, Taiwan Approvals
‘Hunterase’, a treatment for Hunter syndrome developed by GC Biopharma, has successively obtained product approval in major Asian countries India and Taiwan.GC Biopharma announced on August 24 that it…
- GC Biopharma wins India, Taiwan approvals for Hunterase IV.
- CDSCO grants India approval; TFDA approves ICV formulation.
- Hunter syndrome affects 1 in 100,000 to 150,000 male children.
Bomet's silent epidemic: How sexual violence crisis hides behind culture, cash and complicity
Sexual violence persists as stakeholders demand tougher action against perpetrators.
From criminalisation to care: Nigeria’s next mental health challenge
The Federal Executive Council’s decision to approve an amendment to decriminalise attempted suicide is an important moment in Nigeria’s mental health journey.
World : South Australia Reports 2nd Suspected Mammal Bird Flu Case In Seal
CANBERRA, Aug 24 (Bernama-Xinhua) -- South Australian authorities on Monday reported a second suspected case of H5N1 bird flu in a seal, one day after the state reported Australia's first case in a…